Scopus Biopharma Analysis
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Scopus Biopharma is overvalued with Real Value of 0.095 and Hype Value of 0.1. The main objective of Scopus Biopharma otc analysis is to determine its intrinsic value, which is an estimate of what Scopus Biopharma is worth, separate from its market price. There are two main types of Scopus Biopharma's stock analysis: fundamental analysis and technical analysis.
The Scopus Biopharma otc stock is traded in the USA on OTCMKTS Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Scopus |
Scopus OTC Stock Analysis Notes
About 51.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.51. Scopus Biopharma had not issued any dividends in recent years. Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.The quote for Scopus Biopharma is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Scopus Biopharma contact the company at 212 479 2513 or learn more at https://scopusbiopharma.com.Scopus Biopharma Investment Alerts
| Scopus Biopharma is not yet fully synchronised with the market data | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
Scopus Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Scopus Biopharma's market, we take the total number of its shares issued and multiply it by Scopus Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Scopus Biopharma Outstanding Bonds
Scopus Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Scopus Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Scopus bonds can be classified according to their maturity, which is the date when Scopus Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Scopus Biopharma Predictive Daily Indicators
Scopus Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Scopus Biopharma otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Scopus OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Scopus Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Scopus shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Scopus Biopharma. By using and applying Scopus OTC Stock analysis, traders can create a robust methodology for identifying Scopus entry and exit points for their positions.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Scopus Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |